Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy

Michelle E. LeBlanc, Weiwen Wang, Xiuping Chen, Nora B. Caberoy, Feiye Guo, Chen Shen, Yanli Ji, Hong Tian, Hui Wang, Rui Chen, Wei Li

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) is a leading cause of vision loss with retinal vascular leakage and/or neovascularization. Current antiangiogenic therapy against vascular endothelial growth factor (VEGF) has limited efficacy. In this study, we applied a new technology of comparative ligandomics to diabetic and control mice for the differential mapping of disease-related endothelial ligands. Secretogranin III (Scg3) was discovered as a novel disease-associated ligand with selective binding and angiogenic activity in diabetic but not healthy vessels. In contrast, VEGF bound to and induced angiogenesis in both diabetic and normal vasculature. Scg3 and VEGF signal through distinct receptor pathways. Importantly, Scg3-neutralizing antibodies alleviated retinal vascular leakage in diabetic mice with high efficacy. Furthermore, anti-Scg3 prevented retinal neovascularization in oxygen-induced retinopathy mice, a surrogate model for retinopathy of prematurity (ROP). ROP is the most common cause of vision impairment in children, with no approved drug therapy. These results suggest that Scg3 is a promising target for novel antiangiogenic therapy of DR and ROP.

Original languageEnglish (US)
Pages (from-to)1029-1047
Number of pages19
JournalJournal of Experimental Medicine
Volume214
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Retinopathy of Prematurity
Diabetic Retinopathy
Retinal Neovascularization
Vascular Endothelial Growth Factor A
Retinal Vessels
Ligands
Neutralizing Antibodies
Therapeutics
Oxygen
Technology
Drug Therapy
secretogranin III

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. / LeBlanc, Michelle E.; Wang, Weiwen; Chen, Xiuping; Caberoy, Nora B.; Guo, Feiye; Shen, Chen; Ji, Yanli; Tian, Hong; Wang, Hui; Chen, Rui; Li, Wei.

In: Journal of Experimental Medicine, Vol. 214, No. 4, 01.04.2017, p. 1029-1047.

Research output: Contribution to journalArticle

LeBlanc, ME, Wang, W, Chen, X, Caberoy, NB, Guo, F, Shen, C, Ji, Y, Tian, H, Wang, H, Chen, R & Li, W 2017, 'Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy', Journal of Experimental Medicine, vol. 214, no. 4, pp. 1029-1047. https://doi.org/10.1084/jem.20161802
LeBlanc, Michelle E. ; Wang, Weiwen ; Chen, Xiuping ; Caberoy, Nora B. ; Guo, Feiye ; Shen, Chen ; Ji, Yanli ; Tian, Hong ; Wang, Hui ; Chen, Rui ; Li, Wei. / Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. In: Journal of Experimental Medicine. 2017 ; Vol. 214, No. 4. pp. 1029-1047.
@article{f7a9e36ce93d4ecb8982c4ea4eef253a,
title = "Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy",
abstract = "Diabetic retinopathy (DR) is a leading cause of vision loss with retinal vascular leakage and/or neovascularization. Current antiangiogenic therapy against vascular endothelial growth factor (VEGF) has limited efficacy. In this study, we applied a new technology of comparative ligandomics to diabetic and control mice for the differential mapping of disease-related endothelial ligands. Secretogranin III (Scg3) was discovered as a novel disease-associated ligand with selective binding and angiogenic activity in diabetic but not healthy vessels. In contrast, VEGF bound to and induced angiogenesis in both diabetic and normal vasculature. Scg3 and VEGF signal through distinct receptor pathways. Importantly, Scg3-neutralizing antibodies alleviated retinal vascular leakage in diabetic mice with high efficacy. Furthermore, anti-Scg3 prevented retinal neovascularization in oxygen-induced retinopathy mice, a surrogate model for retinopathy of prematurity (ROP). ROP is the most common cause of vision impairment in children, with no approved drug therapy. These results suggest that Scg3 is a promising target for novel antiangiogenic therapy of DR and ROP.",
author = "LeBlanc, {Michelle E.} and Weiwen Wang and Xiuping Chen and Caberoy, {Nora B.} and Feiye Guo and Chen Shen and Yanli Ji and Hong Tian and Hui Wang and Rui Chen and Wei Li",
year = "2017",
month = "4",
day = "1",
doi = "10.1084/jem.20161802",
language = "English (US)",
volume = "214",
pages = "1029--1047",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "4",

}

TY - JOUR

T1 - Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy

AU - LeBlanc, Michelle E.

AU - Wang, Weiwen

AU - Chen, Xiuping

AU - Caberoy, Nora B.

AU - Guo, Feiye

AU - Shen, Chen

AU - Ji, Yanli

AU - Tian, Hong

AU - Wang, Hui

AU - Chen, Rui

AU - Li, Wei

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Diabetic retinopathy (DR) is a leading cause of vision loss with retinal vascular leakage and/or neovascularization. Current antiangiogenic therapy against vascular endothelial growth factor (VEGF) has limited efficacy. In this study, we applied a new technology of comparative ligandomics to diabetic and control mice for the differential mapping of disease-related endothelial ligands. Secretogranin III (Scg3) was discovered as a novel disease-associated ligand with selective binding and angiogenic activity in diabetic but not healthy vessels. In contrast, VEGF bound to and induced angiogenesis in both diabetic and normal vasculature. Scg3 and VEGF signal through distinct receptor pathways. Importantly, Scg3-neutralizing antibodies alleviated retinal vascular leakage in diabetic mice with high efficacy. Furthermore, anti-Scg3 prevented retinal neovascularization in oxygen-induced retinopathy mice, a surrogate model for retinopathy of prematurity (ROP). ROP is the most common cause of vision impairment in children, with no approved drug therapy. These results suggest that Scg3 is a promising target for novel antiangiogenic therapy of DR and ROP.

AB - Diabetic retinopathy (DR) is a leading cause of vision loss with retinal vascular leakage and/or neovascularization. Current antiangiogenic therapy against vascular endothelial growth factor (VEGF) has limited efficacy. In this study, we applied a new technology of comparative ligandomics to diabetic and control mice for the differential mapping of disease-related endothelial ligands. Secretogranin III (Scg3) was discovered as a novel disease-associated ligand with selective binding and angiogenic activity in diabetic but not healthy vessels. In contrast, VEGF bound to and induced angiogenesis in both diabetic and normal vasculature. Scg3 and VEGF signal through distinct receptor pathways. Importantly, Scg3-neutralizing antibodies alleviated retinal vascular leakage in diabetic mice with high efficacy. Furthermore, anti-Scg3 prevented retinal neovascularization in oxygen-induced retinopathy mice, a surrogate model for retinopathy of prematurity (ROP). ROP is the most common cause of vision impairment in children, with no approved drug therapy. These results suggest that Scg3 is a promising target for novel antiangiogenic therapy of DR and ROP.

UR - http://www.scopus.com/inward/record.url?scp=85021901880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021901880&partnerID=8YFLogxK

U2 - 10.1084/jem.20161802

DO - 10.1084/jem.20161802

M3 - Article

C2 - 28330905

AN - SCOPUS:85021901880

VL - 214

SP - 1029

EP - 1047

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 4

ER -